Profile data is unavailable for this security.
About the company
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
- Revenue in USD (TTM)68.68m
- Net income in USD-68.52m
- Incorporated2020
- Employees179.00
- LocationRepare Therapeutics Inc7210 Frederick-Banting, Suite 100ST-LAURENT H4S 2A1CanadaCAN
- Websitehttps://www.reparerx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | 0.00 | -129.85m | 140.31m | 128.00 | -- | 0.5898 | -- | -- | -1.80 | -1.80 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -51.44 | -47.21 | -55.69 | -51.07 | -- | -- | -- | -- | -- | -- | 0.0028 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| aTyr Pharma Inc | 588.00k | -57.90m | 141.74m | 56.00 | -- | 1.74 | -- | 241.05 | -0.9047 | -0.9047 | 0.0092 | 1.08 | 0.0049 | -- | 0.4034 | 10,500.00 | -48.51 | -45.45 | -53.89 | -52.74 | -- | -- | -9,846.26 | -784.19 | -- | -- | 0.0202 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Outlook Therapeutics Inc | 0.00 | -94.05m | 141.93m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Century Therapeutics Inc | 2.04m | -131.39m | 144.02m | 152.00 | -- | 0.6472 | -- | 70.53 | -2.04 | -2.04 | 0.031 | 2.63 | 0.0049 | -- | -- | 13,434.21 | -31.52 | -- | -33.04 | -- | -- | -- | -6,434.23 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| CervoMed Inc | 9.65m | -5.04m | 144.19m | 8.00 | -- | 2.89 | -- | 14.94 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Fennec Pharmaceuticals Inc | 48.89m | 2.74m | 144.73m | 36.00 | 135.99 | -- | 52.92 | 2.96 | 0.0389 | 0.0389 | 1.75 | -0.0497 | 1.18 | 1.21 | 6.63 | -- | 6.62 | -73.43 | 7.70 | -84.32 | 95.55 | -- | 5.59 | -383.28 | 7.75 | 1.87 | 1.05 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| ProQR Therapeutics NV | 20.88m | -24.04m | 145.39m | 157.00 | -- | 4.09 | -- | 6.96 | -0.2956 | -0.2956 | 0.2566 | 0.4352 | 0.1406 | -- | -- | 132,979.00 | -15.98 | -35.51 | -20.63 | -40.51 | -- | -- | -113.62 | -926.31 | -- | -- | 0.3687 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Invivyd Inc | 2.26m | -203.84m | 145.72m | 94.00 | -- | 1.04 | -- | 64.36 | -1.80 | -1.80 | 0.0199 | 1.18 | 0.0092 | -- | 1.13 | 24,085.11 | -82.73 | -- | -96.25 | -- | 96.11 | -- | -9,003.40 | -- | 4.57 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Repare Therapeutics Inc | 68.68m | -68.52m | 148.56m | 179.00 | -- | 0.7294 | -- | 2.16 | -1.63 | -1.63 | 1.61 | 4.80 | 0.2558 | -- | 6.34 | 383,703.90 | -25.52 | -23.40 | -30.30 | -26.37 | -- | -- | -99.76 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Quantum-Si Inc | 1.70m | -89.35m | 150.90m | 159.00 | -- | 0.6467 | -- | 88.66 | -0.6302 | -0.6302 | 0.012 | 1.64 | 0.0057 | 0.2321 | 3.68 | 10,704.40 | -29.89 | -- | -30.99 | -- | 53.41 | -- | -5,249.65 | -- | 20.13 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -64.86m | 155.01m | 51.00 | -- | 0.6354 | -- | -- | -1.11 | -1.11 | 0.00 | 4.06 | 0.00 | -- | -- | 0.00 | -27.82 | -- | -29.32 | -- | -- | -- | -- | -- | -- | -- | 0.1075 | -- | -- | -- | -22.20 | -- | -- | -- |
| Adverum Biotechnologies Inc | 0.00 | -99.86m | 156.01m | 121.00 | -- | 0.9285 | -- | -- | -7.99 | -7.99 | 0.00 | 8.08 | 0.00 | -- | -- | 0.00 | -40.33 | -36.39 | -46.64 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Actuate Therapeutics Inc | 0.00 | -27.77m | 156.52m | 6.00 | -- | -- | -- | -- | -1.45 | -1.45 | 0.00 | -0.7114 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -134.25 | -- | -- | -- | -- | -22.74 | -- | -- | -- |
| Achieve Life Sciences Inc | 0.00 | -27.54m | 156.60m | 22.00 | -- | 3.70 | -- | -- | -1.10 | -1.10 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -58.78 | -86.31 | -71.94 | -119.59 | -- | -- | -- | -- | -- | -11.79 | 0.294 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| P3 Health Partners Inc | 1.40bn | -69.48m | 159.51m | 400.00 | -- | 0.4323 | -- | 0.1137 | -0.5821 | -0.5821 | 11.56 | 1.03 | 1.56 | -- | 10.97 | 3,507,143.00 | -20.51 | -- | -110.70 | -- | 0.6223 | 0.1781 | -13.17 | -56.93 | -- | -9.67 | 0.2686 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Seres Therapeutics Inc | 374.00k | -162.11m | 160.00m | 233.00 | -- | -- | -- | 427.81 | -1.18 | -1.18 | 0.0027 | -0.5742 | 0.001 | -- | 0.0286 | 1,605.15 | -44.53 | -41.51 | -59.82 | -54.13 | -- | -- | -43,343.58 | -170.14 | 0.889 | -17.64 | 6.65 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
Data as of Sep 19 2024. Currency figures normalised to Repare Therapeutics Inc's reporting currency: US Dollar USD
43.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 30 Jun 2024 | 10.33m | 24.35% |
| ARK Investment Management LLCas of 30 Jun 2024 | 2.63m | 6.20% |
| Redmile Group LLCas of 30 Jun 2024 | 1.94m | 4.58% |
| Aquilo Capital Management LLCas of 30 Jun 2024 | 956.93k | 2.25% |
| Deep Track Capital LPas of 30 Jun 2024 | 904.26k | 2.13% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 458.70k | 1.08% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 417.93k | 0.99% |
| GSA Capital Partners LLPas of 30 Jun 2024 | 299.65k | 0.71% |
| Nikko Asset Management Americas, Inc.as of 30 Jun 2024 | 277.17k | 0.65% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 269.78k | 0.64% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
